• Data from Furmonertinib studies for EGFR 20 exon insertion mutations presented at ESMO Congress 2021

    On September 16, the preclinical study data and phase Ib clinical study (FAVOUR) data of Furmonertinib, a self-developed third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) of Allist, for the first-line treatment of EGFR 20 exon insertion mutations*were presented for the first time at the European Society for Medical Oncology (ESMO).

    The excellent efficacy and safety performance of Furmonertinib is expected to provide a new option for NSCLC patients with EGFR 20 exon insertion mutations.


    EGFR 20 exon insertion mutations accounts for about 4-12% of all EGFR mutations. Globally, there is a large unmet need in the treatment market of EGFR 20 exon insertion mutations. Currently approved EGFR TKIs around the world have poor efficacy in the treatment of EGFR 20 exon insertion mutations. No therapy targeting EGFR 20 exon insertion mutations has been approved in China yet. The initial result of the FAVOUR study is expected to make Furmonertinib a potential new option.

    Through high-quality clinical studies, Allist is accelerating the development of multiple new indications for Furmonertinib, establishing its position in the therapeutic field of NSCLC with EGFR 20 exon insertion mutations in China, and reshaping the treatment prospect of NSCLC with EGFR 20 exon insertion mutations. In addition to the FAVOUR study, The phase III clinical study of Furmonertinib for the first line treatment of EGFR-sensitive advanced NSCLC (FURLONG) is expected to be submitted for NDA this year. The FORWARD study of Furmonertinib as an adjuvant therapy was officially launched in April 2021, and is currently recruiting subjects.

    Jinhao Du, Allist Chairman stated that since its inception, Allist has set its vision of "making Chinese new drugs accessible to all", taken "innovate to benefit the people" as its mission, and "In China For Global". Furmonertinib is the first blockbuster product of Allist in oncology, and Allist is accelerating the expansion of the depth and breadth of its oncology product pipeline. Allist's innovation is guided by satisfying the unmet needs of patients. Through independent research and development, cooperative introduction and joint development, Allist is committed to continuously offering Chinese innovative drugs with proven efficacy and accessible for all, to benefit patients in China and around the world.

    About Allist

    Founded in March 2004, Shanghai Allist Pharmaceuticals Co., Ltd. is an innovative drug developer, producer and seller dedicated to the field of lung cancer treatment oriented toward the demands in the global pharmaceutical market. With the philosophy of innovation for life, Allist has set the paramount target of developing first-in-class and best-in-class medicines. After 16 years of unremitting efforts, Allist now boasts strong comprehensive competitiveness in developing and producing on a continuous basis effective and optimal anti-cancer new drugs with independent intellectual property rights.On December 2, 2020, Shanghai Allist Pharmaceuticals Co., Ltd. went public on the STAR market via the Shanghai Stock Exchange (Stock code: 688578).